- Company
- A single tech export brings in 11 times the annual revenue
- by Chon, Seung-Hyun Jan 13, 2022 06:05am
- The biotechnology company ABL Bio signed a mega-deal and secured 11 times its annual revenue through a single license agreement. Its upfront payment by itself ranks in the top 5 among the technology export deals made by pharmaceutical and biopharmaceutical companies in Korea. When excluding the ones that have returned the rights, ABL Bio’s deal
- Company
- Viatris & J&J hired female executives
- by Eo, Yun-Ho Jan 12, 2022 06:05am
- Executive-level personnel in charge of multinational pharmaceutical's external cooperation department are active. According to related industries, Viatris Korea appointed Kim Ji-young (52 years old), former executive director of Janssen Korea, as the head of the dept. of Foreign Cooperation in December last year, while Johnson & Johnson Korea
- Company
- Keytruda-Renvima has been approved as the primary treatment
- by Jan 12, 2022 06:05am
- MSD Korea announced on the 11th that a combination therapy of anti-PD-1 immuno-cancer drug Keytruda (Pembrolizumab) and Lenvima (Lenvatinib) has been approved by the MFDS as the primary treatment for advanced new cell carcinoma. Combination therapy of Keytruda and Lenvima in renal cell cancer treatment recorded 23.9 months of mPFS and impr
- Company
- Reducing # of sales positions of pharmaceutical companies
- by Moon, sung-ho Jan 12, 2022 06:04am
- It was found that the number of personnel engaged in the control and bio industries has steadily increased over the report showed. However, amid the boom in pharmaceuticals and bio, the position of sales workers is decreasing day by day. Analysts say this is because it is concentrated on the development of online sales and marketing and contract
- Company
- Pharmaceutical bio jobs to be reorganized
- by Chon, Seung-Hyun Jan 12, 2022 06:04am
- Jobs in the pharmaceutical bio industry have increased by more than 50% in the past nine years. The number of production workers surged. In recent years, it is analyzed that many jobs have been created in production jobs as pharmaceutical bio companies have greatly increased production facilities and expanded their CMO business. The proportion o
- Company
- Soliris at risk of price cuts amid increasing PA rejections
- by Moon, sung-ho Jan 12, 2022 06:04am
- The National Health Insurance Service has selected ‘Soliris (eculizumab)’ as a ‘subject for PVA monitoring’ and began monitoring its claims amount, believing that its use has increased over a certain level. However, all of the prior authorization applications for the same drug had been rejected last month. In other words, the drug is doub
- Company
- Ultra-high-priced ‘Kymriah’ is up for DREC deliberations
- by Eo, Yun-Ho Jan 11, 2022 06:29am
- Whether the new CAR-T therapy ‘Kymriah’ will be applied insurance benefit is receiving wide attention. According to industry sources, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy ‘Kymriah' will be deliberated as an agenda by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Commi
- Company
- Keytruda's reimbursment to be deliberated at DREC meeting
- by Eo, Yun-Ho Jan 10, 2022 05:56am
- The immuno-oncology drug ‘Keytruda’ is finally on its next step to reimbursement after passing Cancer Disease Deliberation Committee's review. According to industry sources, reimbursement expansion of MSD Korea’s PD-1 inhibitor Keytruda (pembrolizumab) will be deliberated by the National Health Insurance Service’s Drug Reimbursement E
- Company
- Heads of 4 MNCs were newly appointed last year… increase of
- by Eo, Yun-Ho Jan 7, 2022 06:06am
- Four multinational pharmaceutical companies have appointed new CEOs over the past year. According to Dailypharm’s update of CEOs in 32 major multinational pharmaceutical companies, including the Korean Research-based Pharmaceutical Industry Association, heads of 4 pharmaceutical companies were replaced or newly appointed last year. Mo
- Company
- Ahn to reduce generic price to counter Lee's hair loss reimb
- by Kim, Jin-Gu Jan 7, 2022 06:06am
- Cheol-Soo Ahn, the presidential candidate of the minor opposition People's Party, pledged to reduce the price of hair loss drug generics. Ahn prosed this as an alternative in concern over the worsening insurance finances that may be caused by Democratic Party Jae-Myung Lee’s mention of reimbursing hair loss treatments On the 5th, Ahn
